| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.14 | 6e-05 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.19 | 0.0006 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.0008 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0008 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | -0.097 | 0.002 |
| mRNA | navitoclax:birinapant (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |